In vitro co-culture models of breast cancer metastatic progression towards bone

International Journal of Molecular Sciences

Volumn 17, Issue 9, 2016, Pages

  Arrigoni, Chiara ^a   Bersini, Simone ^a   Gilardi, Mara ^a,b   Moretti, Matteo ^a,c,d,e  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^d Swiss Institute of Regenerative Medicine (SIRM)   (Switzerland)

^e DIVISION OF CARDIOLOGY   (Switzerland)

Author keywords

Bone metastasis; Breast carcinoma; Co culture; In vitro models

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ALPHA SMOOTH MUSCLE ACTIN; CHEMOKINE RECEPTOR CXCR; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; COLLAGENASE 3; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; INTERLEUKIN 6; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NOTCH3 RECEPTOR; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN ZO1; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL CADHERIN;

BONE CELL; BONE MARROW STROMA CELL; BONE METASTASIS; BONE TISSUE; BREAST CANCER; CANCER GROWTH; CELL MIGRATION; COCULTURE; DORMANCY; EXTRAVASATION; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; MCF 7 CELL LINE; NONHUMAN; OSTEOLYSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; BONE TUMOR; BREAST TUMOR; COMPLICATION; DISEASE COURSE; FEMALE; METABOLISM; SECONDARY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DISEASE PROGRESSION; FEMALE; HUMANS;

EID: 84983426930     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17091405     Document Type: Review

References (84)

1. Coleman, R.E. Skeletal complications of malignancy. Cancer 1997, 80, 1588–1594.
2. Kroep, J.R.; Charehbili, A.; Coleman, R.E.; Aft, R.L.; Hasegawa, Y.; Winter, M.C.; Weilbaecher, K.; Akazawa, K.; Hinsley, S.; Putter, H. et al. Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. Eur. J. Cancer 2016, 54, 57–63.
3. Chaffer, C.L.; Weinberg, R.A. A perspective on cancer cell metastasis. Science 2011, 331, 1559–1564.
4. Reymond, N.; d’Agua, B.B.; Ridley, A.J. Crossing the endothelial barrier during metastasis. Nat. Rev. Cancer 2013, 13, 858–870.
5. Fazilaty, H.; Mehdipour, P. Genetics of breast cancer bone metastasis: A sequential multistep pattern. Clin. Exp. Metastasis 2014, 31, 595–612.
6. Futakuchi, M.; Fukamachi, K.; Suzui, M. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer. Adv. Drug Deliv. Rev. 2016, 99, 206–211.
7. Simmons, J.K.; Hildreth, B.E.; Supsavhad, W.; Elshafae, S.M.; Hassan, B.B.; Dirksen, W.P.; Toribio, R.E.; Rosol, T.J. Animal models of bone metastasis. Vet. Pathol. 2015, 52, 827–841.
8. Yin, S.; Fan, Y.; Zhang, H.; Zhao, Z.; Hao, Y.; Li, J.; Sun, C.; Yang, J.; Yang, Z.; Yang, X. et al. Differential TGF-β pathway targeting by miR-122 in humans and mice affects liver cancer metastasis. Nat. Commun. 2016, 7, 11012–11025.
9. Evans, J.P.; Sutton, P.A.; Winiarski, B.K.; Fenwick, S.W.; Malik, H.Z.; Vimalachandran, D.; Tweedle, E.M.; Costello, E.; Palmer, D.H.; Park, B.K. et al. From mice to men: Murine models of colorectal cancer for use in translational research. Crit. Rev. Oncol. Hematol. 2016, 98, 94–105.
10. Shologu, N.; Szegezdi, E.; Lowery, A.; Kerin, M.; Pandit, A.; Zeugolis, D.I. Recreating complex pathophysiologies in vitro with extracellular matrix surrogates for anticancer therapeutics screening. Drug Discov. Today 2016.
11. Sanford, K.K.; Barker, B.E.; Woods, M.W.; Parshad, R.; Law, L.W. Search for “indicators” of neoplastic conversion in vitro. J. Natl. Cancer Inst. 1967, 39, 705–733.
12. Haskell, C.M.; Sullivan, A. Comparative survival in tissue culture of normal and neoplastic human cells exposed to adriamycin. Cancer Res. 1974, 34, 2991–2994.
13. Junttila, M.R.; de Sauvage, F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501, 346–354.
14. Katt, M.E.; Placone, A.L.; Wong, A.D.; Xu, Z.S.; Searson, P.C. In vitro tumor models: Advantages, disadvantages, variables, and selecting the right platform. Front. Bioeng. Biotechnol. 2016, 4, 12–26.
15. Bersini, S.; Jeon, J.S.; Moretti, M.; Kamm, R.D. In vitro models of the metastatic cascade: From local invasion to extravasation. Drug Discov. Today 2014, 19, 735–742.
16. Krishnan, V.; Vogler, E.A.; Sosnoski, D.M.; Mastro, A.M. In vitro mimics of bone remodeling and the vicious cycle of cancer in bone. J. Cell. Physiol. 2014, 229, 453–462.
17. Holen, I.; Nutter, F.; Wilkinson, J.M.; Evans, C.A.; Avgoustou, P.; Ottewell, P.D. Human breast cancer bone metastasis in vitro and in vivo: A novel 3D model system for studies of tumour cell-bone cell interactions. Clin. Exp. Metastasis 2015, 32, 689–702.
18. Horas, K.; Zheng, Y.; Zhou, H.; Seibel, M.J. Animal models for breast cancer metastasis to bone: Opportunities and limitations. Cancer Investig. 2015, 33, 459–468.
19. Taubenberger, A.V. In vitro microenvironments to study breast cancer bone colonisation. Adv. Drug Deliv. Rev. 2014, 79, 135–144.
20. Hess, K.R.; Pusztai, L.; Buzdar, A.U.; Hortobagyi, G.N. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res. Treat. 2003, 78, 105–118.
21. Sasser, A.K.; Sullivan, N.J.; Studebaker, A.W.; Hendey, L.F.; Axel, A.E.; Hall, B.M. Interleukin-6 is a potent growth factor for ER-α-positive human breast cancer. FASEB J. 2007, 21, 3763–3770.
22. Wang, J.; Jarrett, J.; Huang, C.C.; Satcher, R.L.; Levenson, A.S. Identification of estrogen-responsive genes involved in breast cancer metastases to the bone. Clin. Exp. Metastasis 2007, 24, 411–422.
23. Koenders, P.G.; Beex, L.V.; Langens, R.; Kloppenborg, P.W.; Smals, A.G.; Benraad, T.J. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The breast cancer study group. Breast Cancer Res. Treat. 1991, 18, 27–32.
24. Wesseling, J.; Van Der Valk, S.W.; Hilkens, J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell 1996, 7, 565–577.
25. Yue, L.; Bao, Z.; Li, J. Expression of MacMARCKS restores cell adhesion to ICAM-1-coated surface. Cell Adhes. Commun. 2000, 7, 359–366.
26. Cooper, C.R.; Sikes, R.A.; Nicholson, B.E.; Sun, Y.X.; Pienta, K.J.; Taichman, R.S. Cancer cells homing to bone: The significance of chemotaxis and cell adhesion. Cancer Treat. Res. 2004, 118, 291–309.
27. Pohorelic, B.; Singh, R.; Parkin, S.; Koro, K.; Yang, A.D.; Egan, C.; Magliocco, A. Role of SRC in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment. Breast Cancer Res. Treat. 2012, 133, 201–214.
28. Burger, J.A.; Kipps, T.J. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107, 1761–1767.
29. Uygur, B.; Wu, W.S. Slug promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol. Cancer 2011, 10, 139–154.
30. Nagasawa, T. CXCL12/SDF-1 and CXCR4. Front. Immunol. 2015, 6, 301–304.
31. Guo, D.; Huang, J.; Gong, J. Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer. Mol. Cell. Biochem. 2012, 363, 179–190.
32. Olbrich, T.; Ziegler, E.; Turk, G.; Schubert, A.; Emons, G.; Grundker, C. Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: Evidence for a dose-window effect. Gynecol. Oncol. 2010, 119, 571–578.
33. Makri, A.; Pissimissis, N.; Lembessis, P.; Polychronakos, C.; Koutsilieris, M. The kisspeptin (KISS-1)/GPR54 system in cancer biology. Cancer Treat. Rev. 2008, 34, 682–692.
34. Hinsche, O.; Girgert, R.; Emons, G.; Grundker, C. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells. Int. J. Oncol. 2015, 46, 878–884.
35. Marriott, I.; Gray, D.L.; Rati, D.M.; Fowler, V.G.; Stryjewski, M.E.; Levin, L.S.; Hudson, M.C.; Bost, K.L. Osteoblasts produce monocyte chemoattractant protein-1 in a murine model of staphylococcus aureus osteomyelitis and infected human bone tissue. Bone 2005, 37, 504–512.
36. Molloy, A.P.; Martin, F.T.; Dwyer, R.M.; Griffin, T.P.; Murphy, M.; Barry, F.P.; O’Brien, T.; Kerin, M.J. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int. J. Cancer 2009, 124, 326–332.
37. Bussard, K.M.; Venzon, D.J.; Mastro, A.M. Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. J. Cell. Biochem. 2010, 111, 1138–1148.
38. Sceneay, J.; Smyth, M.J.; Moller, A. The pre-metastatic niche: Finding common ground. Cancer Metastasis Rev. 2013, 32, 449–464.
39. Chiovaro, F.; Martina, E.; Bottos, A.; Scherberich, A.; Hynes, N.E.; Chiquet-Ehrismann, R. Transcriptional regulation of tenascin-W by TGF-β signaling in the bone metastatic niche of breast cancer cells. Int. J. Cancer 2015, 137, 1842–1854.
40. Wobus, M.; List, C.; Dittrich, T.; Dhawan, A.; Duryagina, R.; Arabanian, L.S.; Kast, K.; Wimberger, P.; Stiehler, M.; Hofbauer, L.C. et al. Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. Int. J. Cancer 2015, 136, 44–54.
41. Oskarsson, T.; Massague, J. Extracellular matrix players in metastatic niches. EMBO J. 2012, 31, 254–256.
42. Scherberich, A.; Tucker, R.P.; Samandari, E.; Brown-Luedi, M.; Martin, D.; Chiquet-Ehrismann, R. Murine tenascin-W: A novel mammalian tenascin expressed in kidney and at sites of bone and smooth muscle development. J. Cell Sci. 2004, 117, 571–581.
43. Massague, J.; Obenauf, A.C. Metastatic colonization by circulating tumour cells. Nature 2016, 529, 298–306.
44. Corcoran, K.E.; Trzaska, K.A.; Fernandes, H.; Bryan, M.; Taborga, M.; Srinivas, V.; Packman, K.; Patel, P.S.; Rameshwar, P. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS ONE 2008, 3, e2563
45. Bersini, S.; Jeon, J.S.; Dubini, G.; Arrigoni, C.; Chung, S.; Charest, J.L.; Moretti, M.; Kamm, R.D. A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. Biomaterials 2014, 35, 2454–2461.
46. 3 adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. Eur. J. Cancer 2013, 49, 482–491.
47. Jeon, J.S.; Bersini, S.; Gilardi, M.; Dubini, G.; Charest, J.L.; Moretti, M.; Kamm, R.D. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc. Natl. Acad. Sci. USA 2015, 112, 214–219.
48. Ghajar, C.M.; Peinado, H.; Mori, H.; Matei, I.R.; Evason, K.J.; Brazier, H.; Almeida, D.; Koller, A.; Hajjar, K.A.; Stainier, D.Y. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 2013, 15, 807–817.
49. Kingsley, L.A.; Fournier, P.G.; Chirgwin, J.M.; Guise, T.A. Molecular biology of bone metastasis. Mol. Cancer Ther. 2007, 6, 2609–2617.
50. Rajski, M.; Vogel, B.; Baty, F.; Rochlitz, C.; Buess, M. Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS ONE 2012, 7, e29743.
51. 2+ signaling in bone-metastatic prostate and breast cancer cells. Clin. Exp. Metastasis 2009, 26, 955–964.
52. Valastyan, S.; Weinberg, R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011, 147, 275–292.
53. Marlow, R.; Honeth, G.; Lombardi, S.; Cariati, M.; Hessey, S.; Pipili, A.; Mariotti, V.; Buchupalli, B.; Foster, K.; Bonnet, D. et al. A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res. 2013, 73, 6886–6899.
54. Zhou, Y.; Zuo, D.; Wang, M.; Zhang, Y.; Yu, M.; Yang, J.; Yao, Z. Effect of truncated neurokinin-1 receptor expression changes on the interaction between human breast cancer and bone marrow-derived mesenchymal stem cells. Genes Cells 2014, 19, 676–691.
55. Ono, M.; Kosaka, N.; Tominaga, N.; Yoshioka, Y.; Takeshita, F.; Takahashi, R.U.; Yoshida, M.; Tsuda, H.; Tamura, K.; Ochiya, T. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 2014.
56. Lim, P.K.; Bliss, S.A.; Patel, S.A.; Taborga, M.; Dave, M.A.; Gregory, L.A.; Greco, S.J.; Bryan, M.; Patel, P.S.; Rameshwar, P. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011, 71, 1550–1560.
57. Sosnoski, D.M.; Norgard, R.J.; Grove, C.D.; Foster, S.J.; Mastro, A.M. Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment. Clin. Exp. Metastasis 2015, 32, 335–344.
58. Chen, Y.C.; Sosnoski, D.M.; Mastro, A.M. Breast cancer metastasis to the bone: Mechanisms of bone loss. Breast Cancer Res. 2010, 12, 215.
59. Canon, J.; Bryant, R.; Roudier, M.; Branstetter, D.G.; Dougall, W.C. Rankl inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res. Treat. 2012, 135, 771–780.
60. Morrison, C.; Mancini, S.; Cipollone, J.; Kappelhoff, R.; Roskelley, C.; Overall, C. Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: Role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis. J. Biol. Chem. 2011, 286, 34271–34285.
61. David, L.W.; Theresa, A.G. Cancer-associated muscle weakness: What’s bone got to do with it. Bonedey Rep. 2015.
62. Chen, Y.; Shi, H.Y.; Stock, S.R.; Stern, P.H.; Zhang, M. Regulation of breast cancer-induced bone lesions by β-catenin protein signaling. J. Biol. Chem. 2011, 286, 42575–42584.
63. Nakajima, K.; Kho, D.H.; Yanagawa, T.; Harazono, Y.; Gao, X.; Hogan, V.; Raz, A. Galectin-3 inhibits osteoblast differentiation through Notch signaling. Neoplasia 2014, 16, 939–949.
64. Zhang, Z.; Wang, H.; Ikeda, S.; Fahey, F.; Bielenberg, D.; Smits, P.; Hauschka, P.V. Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis. Am. J. Pathol. 2010, 177, 1459–1469.
65. Li, X.Q.; Du, X.; Li, D.M.; Kong, P.Z.; Sun, Y.; Liu, P.F.; Wang, Q.S.; Feng, Y.M. ITGBL1 is a RUNX2 transcriptional target and promotes breast cancer bone metastasis by activating the TGF-β signaling pathway. Cancer Res. 2015, 75, 3302–3313.
66. Takahashi, N.; Maeda, K.; Ishihara, A.; Uehara, S.; Kobayashi, Y. Regulatory mechanism of osteoclastogenesis by RANKl and Wnt signals. Front. Biosci. 2011, 16, 21–30.
67. Yao, G.Q.; Sun, B.H.; Weir, E.C.; Insogna, K.L. A role for cell-surface CSF-1 in osteoblast-mediated osteoclastogenesis. Calcif. Tissue Int. 2002, 70, 339–346.
68. Kim, M.S.; Day, C.J.; Morrison, N.A. MCP-1 is induced by receptor activator of nuclear factor-κB ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J. Biol. Chem. 2005, 280, 16163–16169.
69. Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuki, S.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKl. Proc. Natl. Acad. Sci. USA 1998, 95, 3597–3602.
70. Shalhoub, V.; Faust, J.; Boyle, W.J.; Dunstan, C.R.; Kelley, M.; Kaufman, S.; Scully, S.; Van, G.; Lacey, D.L. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J. Cell. Biochem. 1999, 72, 251–261.
71. Liverani, C.; Mercatali, L.; Spadazzi, C.; La Manna, F.; De Vita, A.; Riva, N.; Calpona, S.; Ricci, M.; Bongiovanni, A.; Gunelli, E. et al. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. Bone 2014, 66, 214–222.
72. Nicolin, V.; Bortul, R.; Bareggi, R.; Baldini, G.; Martinelli, B.; Narducci, P. Breast adenocarcinoma MCF-7 cell line induces spontaneous osteoclastogenesis via a RANK-ligand-dependent pathway. Acta Histochem. 2008, 110, 388–396.
73. Arrigoni, C.; De Luca, P.; Gilardi, M.; Previdi, S.; Broggini, M.; Moretti, M. Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKl/OPG ratio in human breast cancer cells generating bone metastases. Mol. Cancer 2014, 13, 238–244.
74. Wang, H.; Yu, C.; Gao, X.; Welte, T.; Muscarella, A.M.; Tian, L.; Zhao, H.; Zhao, Z.; Du, S.; Tao, J. et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 2015, 27, 193–210.
75. Zhao, H.; Ning, L.L.; Wang, Z.Y.; Li, H.T.; Qiao, D.; Yao, Y.; Qin, H.L. Calcitonin gene-related peptide inhibits osteolytic factors induced by osteoblast in co-culture system with breast cancer. Cell Biochem. Biophys. 2014, 70, 1097–1104.
76. Zheng, Y.; Chow, S.O.; Boernert, K.; Basel, D.; Mikuscheva, A.; Kim, S.; Fong-Yee, C.; Trivedi, T.; Buttgereit, F.; Sutherland, R.L. et al. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKl signaling pathways. J. Bone Miner. Res. 2014, 29, 1938–1949.
77. Zhu, J.; Jia, X.; Xiao, G.; Kang, Y.; Partridge, N.C.; Qin, L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: Implications for osteolytic bone metastases. J. Biol. Chem. 2007, 282, 26656–26664.
78. Kapoor, P.; Suva, L.J.; Welch, D.R.; Donahue, H.J. Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J. Cell. Biochem. 2008, 103, 30–41.
79. Schwartz, M.A.; Chen, C.S. Cell biology. Deconstructing dimensionality. Science 2013, 339, 402–404.
80. Bersini, S.; Gilardi, M.; Arrigoni, C.; Talo, G.; Zamai, M.; Zagra, L.; Caiolfa, V.; Moretti, M. Human in vitro 3D co-culture model to engineer vascularized bone-mimicking tissues combining computational tools and statistical experimental approach. Biomaterials 2016, 76, 157–172.
81. Bongio, M.; Lopa, S.; Gilardi, M.; Bersini, S.; Moretti, M. A 3D vascularized bone remodeling model combining osteoblasts and osteoclasts in a CaP nanoparticle-enriched matrix. Nanomedicine 2016, 11, 1073–1091.
82. Labelle, M.; Begum, S.; Hynes, R.O. Platelets guide the formation of early metastatic niches. Proc. Natl. Acad. Sci. USA 2014, 111, 3053–3061.
83. Spiegel, A.; Brooks, M.W.; Houshyar, S.; Reinhardt, F.; Ardolino, M.; Fessler, E.; Chen, M.B.; Krall, J.A.; DeCock, J.; Zervantonakis, I.K. et al. Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov. 2016, 6, 630–649.
84. Whittle, J.R.; Lewis, M.T.; Lindeman, G.J.; Visvader, J.E. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015, 17, 17–30.